The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAshmore Regulatory News (ASHM)

Share Price Information for Ashmore (ASHM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 186.30
Bid: 186.10
Ask: 186.80
Change: -0.50 (-0.27%)
Spread: 0.70 (0.376%)
Open: 186.50
High: 187.20
Low: 185.60
Prev. Close: 186.80
ASHM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

14 Jul 2017 07:00

RNS Number : 0496L
Ashmore Group PLC
14 July 2017
 

 Ashmore Group plc

+0700 14 July 2017

FOURTH QUARTER ASSETS UNDER MANAGEMENT STATEMENT

Ashmore Group plc ("Ashmore", "the Group"), the specialist Emerging Markets asset manager, announces the following update to its assets under management ("AuM") in respect of the quarter ended 30 June 2017.

Assets under management

Theme

Actual31 March 2017

(US$ billion)

Estimated30 June 2017

(US$ billion)

Movement

Q4 vs Q3

(%)

External debt

12.9

13.3

+3%

Local currency

13.5

13.7

+1%

Corporate debt

5.5

6.3

+15%

Blended debt

13.6

14.6

+7%

Equities

3.1

3.4

+10%

Alternatives

1.4

1.5

+7%

Multi-asset

1.1

1.1

-

Overlay / liquidity

4.8

4.8

-

Total

55.9

58.7

+5%

 

Assets under management increased by US$2.8 billion during the period, comprising positive investment performance of US$1.6 billion and net inflows of US$1.2 billion.

Momentum in gross sales continued across the product range in the quarter and gross redemptions reduced again quarter-on-quarter. Subscriptions were from a diverse range of client types, and included both new mandates and additional allocations from existing clients. Net inflows were delivered in blended debt, corporate debt, equities and alternatives, while flows were flat in external debt, multi-asset and overlay/liquidity. Local currency experienced a net outflow as a consequence of a large institutional account redemption.

Emerging Markets assets continued to deliver good absolute returns during the quarter and outperformed developed world fixed income and equity markets. Ashmore's investment processes generated positive investment performance across its fixed income and equities investment themes, with particularly strong performance in local currency followed by external debt. Performance was flat in multi-asset, alternatives and overlay/liquidity. The Group's investment track record relative to benchmarks remains strong over one, three and five years.

Mark Coombs, Chief Executive Officer, Ashmore Group plc, commented:

"Ashmore has performed well over the past 12 months, delivering a 12% increase in AuM through strong investment performance and net inflows in the past two quarters. Emerging Markets asset prices have started to reflect the resilient fundamentals of the underlying economies and investor activity levels are responding. Looking ahead, there is substantial absolute and relative value still available in Emerging Markets and investor allocations have much further to run from their significantly underweight levels."

 

Notes

1. For the translation of US dollar-denominated balance sheet items, the GBP/USD exchange rate was 1.2946 at 30 June 2017 (30 June 2016: 1.3234; 31 December 2016: 1.2340). For the translation of US dollar management fees, the average GBP/USD exchange rate achieved for the financial year was 1.2766 (FY2015/16: 1.4759).

Ashmore will announce its financial results in respect of the year ended 30 June 2017 on 7 September 2017.

 

For further information please contact:

Ashmore Group plcPaul MeasdayInvestor Relations +44 (0)20 3077 6278

FTI ConsultingAndrew Walton +44 (0)20 3727 1514Kit Dunford +44 (0)20 3727 1143

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFERDSIVLID
Date   Source Headline
18th Apr 20241:11 pmRNSDirectorate Change
15th Apr 20247:00 amRNSTrading Statement
18th Mar 20243:30 pmRNSDirector/PDMR Shareholding
7th Feb 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNSTrading Statement
21st Dec 20239:30 amRNSHolding(s) in Company
11th Dec 202311:21 amRNSDirector/PDMR Shareholding
18th Oct 20232:13 pmRNSResult of AGM
13th Oct 20237:00 amRNSTrading Statement
19th Sep 202311:00 amRNSDirector/PDMR Shareholding
19th Sep 202310:08 amRNSHolding(s) in Company
15th Sep 20235:06 pmRNSHolding(s) in Company
14th Sep 20232:56 pmRNSNotice of AGM
14th Sep 202310:29 amRNSDirector/PDMR Shareholding
6th Sep 20237:00 amRNSFinal Results
14th Jul 20231:51 pmRNSHolding(s) in Company
14th Jul 20237:00 amRNSTrading Statement
11th Jul 20232:10 pmRNSHolding(s) in Company
10th Jul 20232:48 pmRNSHolding(s) in Company
30th Jun 20235:11 pmRNSHolding(s) in Company
29th Jun 20239:09 amRNSHolding(s) in Company
14th Jun 20239:23 amRNSHolding(s) in Company
19th May 20238:35 amRNSDirector Declaration
21st Apr 20237:00 amRNSDirectorate Change
17th Apr 20237:00 amRNSTrading Statement
14th Apr 20239:30 amRNSAGM Statement
31st Mar 20232:33 pmRNSDirector/PDMR Shareholding
17th Mar 202310:21 amRNSDirector/PDMR Shareholding
13th Mar 202310:23 amRNSAudit tender process
8th Mar 20239:48 amRNSHolding(s) in Company
27th Feb 20239:41 amRNSHolding(s) in Company
16th Feb 20234:53 pmRNSHolding(s) in Company
8th Feb 20237:00 amRNSHalf-year Report
3rd Feb 20233:02 pmRNSHolding(s) in Company
25th Jan 20233:25 pmRNSHolding(s) in Company
24th Jan 20236:12 pmRNSHolding(s) in Company
23rd Jan 20239:01 amRNSHolding(s) in Company
19th Jan 20234:55 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSTrading Statement
12th Jan 20233:26 pmRNSHolding(s) in Company
11th Jan 20234:27 pmRNSHolding(s) in Company
9th Jan 20233:13 pmRNSHolding(s) in Company
5th Jan 20235:14 pmRNSHolding(s) in Company
16th Dec 20223:52 pmRNSHolding(s) in Company
8th Nov 20224:20 pmRNSHolding(s) in Company
28th Oct 202210:13 amRNSHolding(s) in Company
14th Oct 20222:11 pmRNSResult of AGM
14th Oct 20227:00 amRNSTrading Statement
5th Oct 20226:03 pmRNSHolding(s) in Company
23rd Sep 20224:56 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.